| Ytd | 153.93% | |
| 1y | 404.55% |
| Open | 104.75 | Prev Close | 105.72 | Low | 102.40 | High | 106.56 | Mkt Cap | 4.41B |
| Vol | 281.73K | Avg Vol | 958.34K | EPS | -4.13 | P/E | -25.60 | Forward P/E | -21.51 |
| Beta | 1.20 | Short Ratio | 7.33 | Inst. Own | 121.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 89.57 | 200-d Avg | 63.83 | 1yr Est | 127.67 |
DNTH News
NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate cla
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its C
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc
NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: D
Company announces $30 million Series A financing and founding leadership team with expertise in pulm
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting ra
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; S
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.85 per share versus the Zack
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders
NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: D
8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of
NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:
114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026. T
JPMorgan Chase and Co. lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 6
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average tra
Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy
Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B.
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
Dow falls 100 pts, Latham Group Inc (SWIM) rises 25.7%, Babcock & Wilcox Enterprises Inc (BW) ga